Kepivance FDA Approval History
FDA Approved: Yes (First approved December 15, 2004)
Brand name: Kepivance
Generic name: palifermin
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Mucositis
Kepivance (palifermin) is a recombinant human keratinocyte growth factor indicated to decrease the incidence and duration of severe oral mucositis.
Development Timeline for Kepivance
|Dec 15, 2004||Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients|
|Jun 24, 2004||Amgen Submits Biologics License Application for FDA Approval of Palifermin|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.